How many times are you going to let your teenage son total your car out before you take the keys away? Could he one day finally figure it out, maybe? But, how many chances are you going to give him? I don't see anything now that would change my mind based upon past history. But, what do I know? I sold out several years ago after owning this thing for over a decade filled with promises. And I lost 99% of my $58,000 waiting. I saw a lot of wrecked cars along the way. A lot of promises afterwards and a continuous pattern of behavior that is reckless with acquisitions followed by his failures afterwards. This company has certainly not been in the best interest of the share"holers". I have been waiting for the day he finally gets it. With all the money thrown at him you would think he finally gets it! But I will not put up one cent any longer to watch this show go on and on and on. You want to pay for admission, and continue to watch this side show be my guest! If $128 million in accumulated deficit is not enough for you to get it then step right up! EQ
A small private placement could tide them over till revs hit $4.5. We are not talking a lot. With the kind statements made by CEO regarding impending future revenues, it could be a fairly easy solution.
CEO says revs may hit $4 M in the coming fiscal year. That's quite a claim: Just look. What if revs. triple every Q from the lowly base of $56,000?
$168,000, $.504M, $1.52M, $4.56.
So the CEO is looking for this type of 300% quarterly sequential!!
Stock goes up if/ when market sees that kind of growth.Presentations to investors would create a stir.
Growth rate could level off to, say 100% YOY. I think, if you read the CC transcript, they would raise the prices too.
TGAL 8-K 2011-11-29
Petaluma, Calif., November 29, 2011 — Tegal Corporation (NASDAQ: TGAL) today announced that it has made a $300,000 strategic investment in NanoVibronix Inc., a private company that develops medical devices and products that implement its proprietary therapeutic ultrasound technology.
“Our investment in NanoVibronix expands the Tegal portfolio to new markets and new commercial horizons,” said Mr. Mika. “NanoVibronix is a technology leader in the application of surface acoustic waves in the treatment of wounds and the prevention of infection in indwelling catheters. Under the leadership of Dr. Harold Jacob, NanoVibronix Chief Executive Officer, the company has demonstrated the scientific merit, safety and efficacy of devices using this technology to address the therapeutic needs of patients and clinicians.”
“Tegal’s investment and management expertise are critical to accelerating the growth of NanoVibronix,” said Dr. Jacob. “We are extremely pleased to partner with Tegal as we take the next step in our corporate growth plan.”
January 20, 2011 09:01 AM Eastern Standard Time
“With this initial investment by Tegal Corporation, we continue our transition from our current position as a third-tier supplier of semiconductor capital equipment to pursuing a leading role in green energy,” said Thomas Mika, President & CEO of Tegal Corporation. “After extensive due diligence, we believe the projects in PV-based solar energy that sequel Power is initiating can make a true difference to the future of many countries looking to reduce their dependence on fossil fuels. The sequel Power model for large scale PV-based solar projects is unique in the industry and has won significant acclaim from governments, industrial companies and industry advocates for its innovation and prospect for success. By forming this new company with this talented team, we can capitalize on this opportunity in what we believe to be the most effective way possible for the benefit of our stockholders, which utilizes Tegal’s capital equipment know-how, a portion of our cash and even potentially the tax benefits of our NOL’s. We look forward to supporting the activities of sequel Power through our direct efforts and through related operations and investments we may make in the future.”
Thomas Mika - TGAL 8-K 2008-12-31
I believe that all of these changes will enable Tegal to ride out the current economic downturn and position the company to emerge as a stronger entity post recession. We are closely focused on improving our sales effort, further increasing the technological advantages of our products and reducing costs across all aspects of our business operations. We are also refining our strategy to address the changing market conditions. I will update you more on our plans on next quarter's conference call. When we emerge from this downturn, we fully intend to be stronger and better positioned than we have ever been in the past, and I am confident that we will achieve that goal.
Well, look at the days behind us and tell me how much better are they? Even that goofball analyst with the $10 Target has they will lose $1.56 a share next year. With less than $2 million in cash, how are those loses going to be funded? Secondary here it comes! I think he is waiting for the money to run out so the share price dips below $1 so they can do their thing and do a reverse spit on the share"holers" first and then the secondary. Mika has never waited this long before. Usually he has been at the well for money a year out, or more. Only wild card in this whole thing is if someone can knock him out and take it over. Maybe that is the best days ahead? Can't be any worse than what's behind them! EQ
"If US healthcare were to use big data creatively and effectively to drive efficiency and quality, the sector could create more than $300 billion in value every year."
Google the article for yourself
We are in a strong position in the market poised for explosive growth and whose need is becoming more apparent every day. Our value proposition and superior product offerings are proven with every new agreement that we signed
I do not believe that CollabRx is fairly valued in the public markets today, but I think that will begin to change now that The market is expected to jump from $2.3 billion in 2012 to $9.1 billion in 2018, according to the firm's findings, and the massive growth points to a market that is firing on many cylinders
the explosion of ..data is expected to outpace the ability of practicing physicians to stay current on the clinical impact of the data. As a result, laboratories that provide such services are increasingly adopting the position of selling "reports", or knowledge, and not simply test results. This [is a] paradigm shift.
Analyst on CC:
Looks like you guys are there commercially. I would like to learn how and when things ramp
**Last week, I wrote a check to pick up 30,417 CollabRx
**explosion of tests .. are likely to occur
**NGS testing in ontology is growing..at about 100% per year
**there are a number of hospitals who [said] they intend to sequence just about every patient that walks through the door that is a cancer patient.
**Break even is ..somewhere between $4 million and $4.5
**...could.. [we]... get to cash break even in our coming fiscal year? ...yes, but with the caveat that we don't give guidance
Sounds like you're short and saying, "holy smokes, Mika actually made a good hire with a guy who has real credibility...for the first time EVER!"
You've got to ask yourself TWO QUESTIONS this morning after this PR news. 1) Why would some big shot from a big company like LIFE (hint!) come to work for a tiny company with one foot in the grave and someone with a big head running it? 2) Why would Mika wait so long to go after YET another secondary like he has never waited this long before and now only has less than $2 million in cash? I think you will discover their next move. Will be interesting to see how long this "new guy" lasts with Mika. Countless others in the past with good credentials were left in this company's wake with Mika still at the helm. This company has been his personal checkbook FOR A VERY LONG TIME! EQ
I totally agree with you lzr723. But, no surprise because we both go way back! But, there is several things to also consider. One, Mika is still on board because of his severance package and will sink any ship he boards. Second, they are very close to doing another secondary unless they did it so fast I missed it. I am shocked Mika waited this long to go out and ask for more money. He does wonders making everyone believe in the dream just around the corner. But, the reality is they only had $50,000 in revenues in the last quarter that was announced. Then this analyst comes out of no where to start coverage but not to recommend any buys or sells have you? Yah, then he puts a $10 target on it? Might as well be $100. I think he is sitting on a sh_t load of shares, part of which were unloaded today. He found out when he wanted to sell some, the toilet here was plugged. Attention any new investors involved in a NEW secondary AGAIN here!!!!!! Unless you remove Mika from management as part of the deal your dollars will slowly be burned and join those that came before you in this money pit and move over into the accumulated deficit of $127 million of this company! Buyers beware here! If this thing is going to the moon, you better make sure it clears the launch pad first! Or even a liftoff! This thing is a dud! How much proof from the past do you need? EQ
Actually it's probably a good time to buy, if you're a true believer. We've seen this behavior before. All it takes is one of Tom's fluff PRs and it could be above $5 in no time. I'm not a believer so I'll hold on to my cash.
Taglich's Company Profile for:
Analyst: Juan Noble
Taglich Rating: Speculative Buy
Price Target: $10.00
Time Horizon: 12 Months
Rating Established: February 25, 2014
Price When Established: $3.42
Most Recent Report: February 25, 2014
Price When Issued: $3.42
Don't quit your day job.
CollabRx Launches New Web App For Cynvenio’s ClearID Breast Cancer Patients
By admin on January 15, 2014
San Francisco, Calif., January 15, 2014 – CollabRx, Inc. (NASDAQ: CLRX), a leading data analytics company, today announced that its newest Therapy Finder for breast cancer patients will be made available in connection with the Cynvenio ClearID™ Breast Cancer genomic blood test. This announcement extends the scope of a previously disclosed multi-year agreement which announced the pairing of the CollabRx Genetic Variant Annotation (GVA) Service™ with tumor mutation profiling from whole blood provided by Cynvenio.
Patients of physicians who order the Cynvenio ClearID™ Breast Cancer genomic blood test will receive an annual subscription to a customized version of the CollabRx Therapy Finder™ app for breast cancer. The ClearID test supports the proactive monitoring of breast cancer survivors at high risk of recurrence, such as triple-negative patients (ER-, PR-, HER2-) CollabRx’s breast cancer Therapy Finder app is a web-based decision support tool that enables patients (and their physicians) to take into account the molecular aspects of a metastatic breast cancer tumor when determining a treatment plan. The Therapy Finder provides for a dynamic user environment to navigate and understand both the current standard of care as well as cutting edge experimental therapy options with the goal of enabling patients to receive the best possible care. The subscription will include access to news and information to provide patient oriented educational material on advances in breast cancer medical and scientific research, risk factors for recurrence, monitoring, and early detection. The breast cancer Therapy Finder is kept dynamically up-to-date and curated by CollabRx medical and scientific personnel with the support of an editorial board composed of independent breast cancer clinical experts. The Therapy Finder for breast cancer is the most recent electronic decision support app released by CollabRx, is first such app developed specifically for a patient user, and complements existing Therapy Finders for lung cancer, colorectal cancer, and melanoma.
“This collaboration will provide breast cancer patients, survivors and their families with two powerful tools in one test,” said André de Fusco, CEO of Cynvenio. “The ClearID Breast Cancer test offers genomic insights from a standard blood draw analyzed by next gen sequencing. By pairing ClearID with the CollabRx Therapy Finder we can now take into account an individual patient’s molecular (tumor) data when offering the latest insights into breast cancer treatments. This is a milestone in our efforts to develop a new standard for individualized breast cancer monitoring.”
“The CollabRx Therapy Finder for breast cancer provides patients with an up-to-date and easily accessible tool to navigate therapy considerations that incorporate molecular data and also receive curated news that pertains to their disease,” said Thomas Mika, Chairman, President & CEO of CollabRx. “We are excited to collaborate with Cynvenio on its introduction with the goal of providing metastatic breast cancer patients with an easy to use tool to aid in treatment planning by contexualizing the state of scientific and medical research backed by sound science.”
The partnership with Cynvenio represents another proof point in CollabRx’s strategy to commercialize multiple newly developed products and services in 2014. This new commercial development attests to the growing adoption of CollabRx technology and interpretive analytics in top-tier laboratories worldwide as a standard aspect of interpretive medical informatics solutions in cancer and other diseases.
Sentiment: Strong Buy
CollabRx and CellNetix Partner to Advance Molecular Testing in Oncology
By admin on January 27, 2014
San Francisco, Calif. January 27, 2014 – CollabRx, Inc. (NASDAQ: CLRX), a data analytics company focused on informing clinical decision making in molecular medicine, and CellNetix Pathology & Laboratories, LLC, a leading anatomic pathology testing and services provider, today announced a multi-year agreement to access CollabRx technology and content resources in support of the clinical interpretation of genetic sequencing-based tests provided by CellNetix.
Under the terms of the agreement, CollabRx medical and scientific knowledge will be incorporated into the results of genetic sequencing-based tests in oncology provided by CellNetix. CellNetix will leverage CollabRx’s dynamically updated knowledgebase in molecular medicine, ensuring that the latest medical and scientific data is made available to ordering physicians to aid in their interpretation of test results and inform patient treatment planning. CollabRx’s knowledgebase includes the clinical impact of specific genetic profiles and is supported by its large and growing network of over 75 leading clinical practitioners in the U.S. and Europe.
The partnership will leverage each company’s commitment to developing cutting edge technology infrastructure and information system applications to integrate, automate, and standardize molecular testing and reporting in oncology. These capabilities are of particular significance in the large-scale molecular analysis of tumors using clinical genetic sequencing, given the sheer volume and complexity of genetic data that is produced. While genetic sequencing based tests are increasingly becoming an important part of the clinical management of cancer patients, the resulting explosion of data is thus far outpacing the ability of practicing physicians to understand how to apply this genetic data in treating their patients.
“CollabRx has developed a highly scalable technology platform and process to provide a key part of the diagnostic test report for clinical genetic sequencing in cancer,” said Pat Cooke, CIO & Executive Director of Business Operations at CellNetix. “These IT tools and services are essential to dynamically associate the latest medical and scientific knowledge with the results of tumor mutation profiling conducted by CellNetix. We are excited to work with CollabRx to provide a best in class medical informatics solution that will enable physicians to take a tumor’s molecular characteristics into consideration when determining a cancer treatment plan.”
“CellNetix has combined peer-to-peer collaboration and clinical expertise with technological innovation to dramatically impact the delivery of healthcare by individual physicians and hospital systems,” said Thomas Mika, Chairman, President & CEO of CollabRx. “CollabRx is privileged to partner with CellNetix, the largest and most comprehensive pathology company in the Pacific Northwest, to link clinical genetic sequencing test results with expert-vetted therapy considerations to result in the best possible care for cancer patients.”
The partnership with CellNetix represents the CollabRx’s first such relationship with a large and influential private pathology company and demonstrates the Company’s accelerating pace of business and channel development in 2014. This new milestone attests to the growing adoption of CollabRx technology and interpretive analytics in top-tier laboratories worldwide as a standard aspect of test reporting for clinical genetic sequencing in cancer and other diseases.
Sentiment: Strong Buy
Someone here asked to show them a stock worse than CLRX. It's hard to find one, but I did. It is ADSU. It was a total FAST SCAM about a month ago the SEC is investigating and is no longer trading now. It had virtually no assets, was supposedly run by a wife or girlfriend of a #$%$, and was pumped on just about every Yahoo "mess"age board. It's still a close one, but I think ADSU takes the cake! CLRX has a much SLOWER DEATH RATE so Mike can fill his pockets. You have to understand that this company is like Mika's checkbook to get the real picture here!!!
Now, as I predicted another dilution is coming very soon. But, the good news is no reverse "spit" on the share"holers" this time!!! Someone here said $10 million bucks! I can't believe someone is going to come in and put $10 million more into this dead stock when the market #$%$" is only around $8 million. But, when Mike opens his pockets everybody comes running and lines up to fill them!!! He is one notch just above the Devil with no guilt conscience. The HIGHLY COMPENSATED guy is evil! His back door is well protected as well with a nice severance package!! SO YOU CAN'T GET RID OF HIM!! EQ